INmune Bio (INMB) News Today → Bill Clinton Backing Biden Replacement??? (From The Freeport Society) (Ad) Free INMB Stock Alerts $9.45 -0.09 (-0.94%) (As of 05/31/2024 ET) Add Compare Share Share HeadlinesStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative May 30 at 8:00 AM | globenewswire.comINmune Bio Inc. to Join Russell 3000® IndexMay 27, 2024 | marketbeat.comINmune Bio, Inc. (NASDAQ:INMB) Stake Lessened by Janney Montgomery Scott LLCJanney Montgomery Scott LLC cut its stake in INmune Bio, Inc. (NASDAQ:INMB - Free Report) by 36.3% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 163,559 shares of the company's stock after sellinMay 13, 2024 | finance.yahoo.comINmune Bio, Inc. (NASDAQ:INMB) Q1 2024 Earnings Call TranscriptMay 12, 2024 | finance.yahoo.comINmune Bio First Quarter 2024 Earnings: EPS Misses ExpectationsMay 11, 2024 | markets.businessinsider.comRobust Pipeline and Financial Stability Underpin Buy Rating for Inmune BioMay 10, 2024 | finanznachrichten.deINmune Bio, Inc.: INmune Bio Inc. Announces First Quarter 2024 Results and Provides Business UpdateMay 9, 2024 | globenewswire.comINmune Bio Inc. Announces First Quarter 2024 Results and Provides Business UpdateMay 7, 2024 | finance.yahoo.comINmune Bio Inc. to Report First Quarter 2024 Financial Results and Provide a Corporate Update on Thursday, May 9May 1, 2024 | msn.comINmune Bio files for $250M mixed shelf offeringApril 30, 2024 | finance.yahoo.comINmune Bio Inc. Provides Update on Two Patients from the Phase 1b Alzheimer’s Disease Trial who Continue to Receive XPro™ Under Compassionate Use for Over Three YearsApril 30, 2024 | globenewswire.comINmune Bio Inc. Provides Update on Two Patients from the Phase 1b Alzheimer's Disease Trial who Continue to Receive XPro™ Under Compassionate Use for Over Three YearsApril 29, 2024 | globenewswire.comINmune Bio Inc. Completes First Cohort and Initiates Second Cohort of Phase 1/2 Study of INKmune™ Natural Killer Cell Therapy in Patients with Metastatic Castration-Resistant Prostate CancerApril 26, 2024 | finance.yahoo.comINmune Bio Independent Director Acquires 80% More StockApril 25, 2024 | markets.businessinsider.comInmune Bio Earns Buy Rating on Positive XPro Developments and Strong FinancialsApril 25, 2024 | globenewswire.comINmune Bio Inc. Announces $9.7 Million Registered Direct Offering Priced At-the-Market Under Nasdaq RulesApril 23, 2024 | globenewswire.comINmune Bio Inc. Announces 24-Month Stability Validation of XPro™ for Phase III Readiness and Commercial Supply Chain Modeling & Development of Novel Immunogenicity AssayApril 22, 2024 | msn.comINmune Bio rises 2%, on $4.5M direct offeringApril 22, 2024 | finance.yahoo.comINmune Bio Inc. Raises Approximately $4.8 Million in Gross Proceeds Through Registered Direct Offering with Officers, Employees and Directors Purchasing Approximately 20% of the OfferingApril 22, 2024 | globenewswire.comINmune Bio Inc. Raises Approximately $4.8 Million in Gross Proceeds Through Registered Direct Offering with Officers, Employees and Directors Purchasing Approximately 20% of the OfferingApril 8, 2024 | finance.yahoo.comINmune Bio Inc. Presents Data on INB03’s Role as an Immune Check Point Modulator in the Treatment of High-Risk Breast Cancer at AACR 2024April 8, 2024 | globenewswire.comINmune Bio Inc. Presents Data on INB03's Role as an Immune Check Point Modulator in the Treatment of High-Risk Breast Cancer at AACR 2024April 2, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Roivant Sciences (ROIV) and Inmune Bio (INMB)April 1, 2024 | finance.yahoo.comINmune Bio, Inc. (NASDAQ:INMB) Q4 2023 Earnings Call TranscriptMarch 31, 2024 | finance.yahoo.comINmune Bio Full Year 2023 Earnings: Revenues Beat Expectations, EPS LagsMarch 30, 2024 | seekingalpha.comINmune Bio, Inc. (INMB) Q4 2023 Earnings Call TranscriptMarch 29, 2024 | finance.yahoo.comINmune Bio Inc (INMB) Posts Year-End Earnings, Reveals Net Loss Amidst Clinical AdvancementsMarch 29, 2024 | finanznachrichten.deINmune Bio, Inc.: INmune Bio Inc. Announces Year End 2023 Results and Provides a Q4 Business UpdateMarch 28, 2024 | globenewswire.comINmune Bio Inc. Announces Year End 2023 Results and Provides a Q4 Business UpdateMarch 26, 2024 | globenewswire.comINmune Bio Inc. to Report Fourth Quarter 2023 Financial Results and Provide a Corporate Update on Thursday, March 28March 13, 2024 | globenewswire.comINmune Bio CSO and Co-Founder Mark Lowdell, Ph.D. Receives The ISCT Career Achievement Award in Cell and Gene TherapyMarch 6, 2024 | finanznachrichten.deINmune Bio, Inc.: INmune Bio Reports Significant EEG Improvement in Alzheimer's Patients Treated with XProMarch 6, 2024 | markets.businessinsider.comBuy Rating Affirmed for Inmune Bio Amid Promising Alzheimer’s Treatment DevelopmentsMarch 5, 2024 | globenewswire.comINmune Bio Reports Significant EEG Improvement in Alzheimer's Patients Treated with XPro™February 28, 2024 | marketbeat.comINmune Bio (INMB) Set to Announce Earnings on ThursdayINmune Bio (NASDAQ:INMB) will be releasing earnings on Thursday, February 29, Yahoo Finance reports.February 17, 2024 | finance.yahoo.comINMB Jun 2024 25.000 callFebruary 16, 2024 | finance.yahoo.comINMB Mar 2024 20.000 callFebruary 16, 2024 | finance.yahoo.comINMB Mar 2024 12.500 putFebruary 15, 2024 | finance.yahoo.comINMB Feb 2024 15.000 putFebruary 12, 2024 | marketbeat.comRhenman & Partners Asset Management AB Decreases Stock Position in INmune Bio, Inc. (NASDAQ:INMB)Rhenman & Partners Asset Management AB cut its holdings in INmune Bio, Inc. (NASDAQ:INMB - Free Report) by 72.0% in the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 50,000 shares of the company's stock afFebruary 12, 2024 | finance.yahoo.comINmune Bio to Participate in the Oppenheimer 34th Annual Healthcare Life Sciences ConferenceFebruary 7, 2024 | finance.yahoo.comINmune Bio to Participate in Baird’s Biotech Discovery Series Webcast on February 13, 2024February 4, 2024 | finance.yahoo.comInsiders own 24% of INmune Bio, Inc. (NASDAQ:INMB) shares but retail investors control 53% of the companyFebruary 1, 2024 | markets.businessinsider.comBuy Rating Affirmed: Inmune Bio’s XPro Progresses with FDA’s Green Light and Unique Therapeutic ApproachFebruary 1, 2024 | msn.comInmune Bio Resumes Alzheimer’s Trial, Aims for Mid-2024 EnrollmentJanuary 31, 2024 | msn.comFDA lifts clinical hold on INmune Bio’s Phase II Alzheimer’s trialJanuary 31, 2024 | markets.businessinsider.comInmune Bio’s Buy Rating Affirmed Amid Positive Alzheimer’s Program DevelopmentsJanuary 31, 2024 | es.investing.comINmune Bio Inc (INMB)January 31, 2024 | bizjournals.comFDA lifts hold on local company's clinical trial for Alzheimer's drugJanuary 30, 2024 | finanznachrichten.deINmune Bio, Inc.: INmune Bio Announces FDA Removal of Clinical Hold for Alzheimer's Disease ProgramJanuary 30, 2024 | marketwatch.comFDA Lifts Clinical Hold on INmune Bio Alzheimer's Program Get INmune Bio News Delivered to You Automatically Sign up to receive the latest news and ratings for INMB and its competitors with MarketBeat's FREE daily newsletter. Email Address Write this ticker symbol down… (Ad)A megatrend now poised to mint a brand-new wave of millionaires right here in America. And today, self-made millionaire Tim Bohen is giving you an inside look at the megatrend that’s going to change everything. Discover the #1 company leading this revolution INMB Media Mentions By Week INMB Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. INMB News Sentiment▼0.560.77▲Average Medical News Sentiment INMB News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. INMB Articles This Week▼42▲INMB Articles Average Week Get INmune Bio News Delivered to You Automatically Sign up to receive the latest news and ratings for INMB and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: X4 Pharmaceuticals News Today Cidara Therapeutics News Today Fortress Biotech News Today Prime Medicine News Today REGENXBIO News Today CARGO Therapeutics News Today HilleVax News Today iTeos Therapeutics News Today Taysha Gene Therapies News Today Valneva News Today Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:INMB) was last updated on 6/2/2024 by MarketBeat.com Staff From Our PartnersBuy this small stock before coming AI Tidal WaveChaikin AnalyticsWrite this ticker symbol down…StocksToTradeTrump’s Gift Could Unleash $51 Billion in New WealthWealthpin ProBill Clinton Backing Biden Replacement???The Freeport SocietyWarren Buffett, Jeff Bezos, Michael Bloomberg, & 48 Members of Congress Are Buying ONE Sector…InvestorPlaceExposed: 10 CENT Crypto to Explode May 20th?True Market InsidersHe Is Giving Away BitcoinCrypto Swap ProfitsShocking $16T Elon Musk Crypto LeakCrypto 101 Media Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding INmune Bio, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.